HealthyWomen Statement on Proposal to Withdrawal Only FDA-Approved Treatment Option for Preterm Birth
HealthyWomen urges the U.S. Food and Drug Administration (FDA) to maintain patient access to Makena (hydroxyprogesterone caproate or 17P), an
Read more